Lupin DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.74×0.78×0.82×0.80×0.62×
0.93×0.92×0.98×0.93×0.78×
26.7%26.6%18.1%13.1%5.5%
0.83×0.83×0.85×0.85×0.74×
1.70×1.70×1.69×1.67×1.83×
26.2%27.1%20.9%13.7%3.6%
26.9%26.9%20.8%14.3%3.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LUPIN₹1,989.90

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹90,978 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.620.800.820.780.74
Interest Burden (Pretax/EBIT) ×0.780.930.980.920.93
EBIT Margin %5.5113.0618.1226.6126.73
Asset Turnover ×0.740.850.850.830.83
Financial Leverage (Assets/Equity) ×1.831.671.691.701.70
ROE (5-step product, year-end total equity) %3.6413.7320.9027.0926.20
ROE (owners' profit / average owners' equity) %3.4914.3120.8426.9026.90
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.